|Payment & Shipping Terms||Supply Capacity|
|Payment Terms:||L/C, T/T, WU||Production Capacity:||6 Kilogram/Year|
|Min. Order:||1 Gram||Packing:||According to the...|
|Means of Transport:||Ocean, Air, Land||Delivery Date:||within 7 days|
Lestaurtinib (CAS: 111358-88-4)
Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine, and is being developed by Cephalon.
It is an inhibitor of FLT3, JAK2,TrkA, TrkB and TrkC.
It is undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders.
As of 2009, it is in Phase II clinical trials for AML and Phase II clinical trials for myeloproliferative disorders.
Category: Antineoplastic Drugs API